BSX Boston ScientificcompanySEC Filings & Insider Trading Activity 2026
Latest Boston Scientific (BSX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 17, 2026, a 10-Q quarterly report filed on November 3, 2025, an 8-K current report filed on April 22, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Boston Scientific (BSX) (SEC CIK 885725), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Medical devices portfolio across Endoscopy, Urology, Neuromodulation, MedSurg, and Cardiovascular segments
- • Cardiovascular strategic shift: Discontinued ACURATE Neo2/Prime Aortic Valve sales globally, ceased pursuit of FDA and other approvals in 2025
Risk Factors
- • Leverage ratio maximum 4.50x as of December 31, 2025, up from 3.75x pre-Axonics acquisition in November 2024
- • Total debt $11.436B at end of 2025, up from $10.746B in 2024, fixed-rate debt $11.393B versus variable $43M
Management Discussion & Analysis
- • No revenue, profitability, segment, or cash flow data disclosed in provided MD&A section
- • Management implementing new global ERP affecting internal controls, phased rollout began August 2025 in EMEA
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • No quarterly revenue or YoY change figures disclosed in MD&A section provided
- • Restructuring charges related to severance, facility closures, product line transfers including ACURATE neo2 and ACURATE Prime discontinuation
Risk Factors
- • No new or updated risk factors disclosed; risk section unchanged from most recent 10-K
- • Legal/compliance risk: multiple directors and officers initiated Rule 10b5-1 trading plans for stock sales through 2026-2027
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • BSX arranged $11B total acquisition financing: $3B 5-year revolver (matures 2031), $2B 364-day revolver, and $6B 364-day delayed-draw term loan
- • All three facilities tied to Penumbra (PEN) acquisition announced Jan 14, 2026; term loan tranches ($1B + $5B) drawable only at deal closing
Item 2.03: Creation of a Direct Financial Obligation
- • BSX entered into 2026 Credit Agreements — full terms/details referenced from a prior section of the same filing
- • Item 2.03 flags a material new financial obligation, indicating new debt or credit facility commitments by BSX
Item 1.02: Termination of a Material Definitive Agreement
- • Terminated 2021 Revolving Credit Agreement (Wells Fargo as agent) on Feb 26, 2026, replaced by new 2026 facility
- • Prior agreement had been amended 3 times since May 2021 inception, signaling active liability management
Annual Reports Archive10-K
AI-powered analysis of Boston Scientific (BSX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Boston Scientific (BSX) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Boston Scientific (BSX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $12.7B | $14.2B | $16.7B | $20.1B |
| Gross Profit | $8.7B | $9.9B | $11.5B | $13.9B |
| Operating Income | — | $2.3B | $2.6B | $3.6B |
| Net Income | — | $1.6B | $1.9B | $2.9B |
| Gross Margin | 68.8% | 69.5% | 68.6% | 69.0% |
| Op. Margin | — | 16.5% | 15.5% | 18.0% |
| Net Margin | — | 11.0% | 11.1% | 14.4% |
| Balance Sheet | ||||
| Total Assets | — | $35.1B | $39.4B | $43.7B |
| Equity | — | $19.3B | $21.8B | $24.2B |
| ROE | — | 8.1% | 8.5% | 12.0% |
Source: XBRL financial data from Boston Scientific (BSX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 22, 2026 | — | — | — |
8-K | Mar 30, 2026 | — | — | — |
8-K | Feb 26, 2026 | — | Analysis | — |
8-K | Feb 23, 2026 | — | Analysis | — |
10-K | Feb 17, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 5, 2026 | — | — | |
8-K | Feb 4, 2026 | — | — | |
8-K | Jan 15, 2026 | — | — | |
8-K | Jan 15, 2026 | — | — | |
10-Q | Nov 3, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 1, 2025 | Jun 30, 2025 | Analysis | |
10-Q | May 1, 2025 | Mar 31, 2025 | Analysis | |
10-K | Feb 18, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 1, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 1, 2024 | Mar 31, 2024 | — | |
10-K | Feb 20, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 1, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 23, 2022 | Dec 31, 2021 | — |
Frequently Asked Questions
What are the latest BSX SEC filings in 2026?
Boston Scientific (BSX) has filed a 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 3, 2025, an 8-K current report on April 22, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did BSX file its most recent 10-K annual report?
Boston Scientific (BSX) filed its most recent 10-K annual report on February 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view BSX 10-Q quarterly reports?
Boston Scientific (BSX)'s most recent 10-Q quarterly report was filed on November 3, 2025. SignalX displays every BSX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has BSX filed recently?
Boston Scientific (BSX)'s most recent 8-K was filed on April 22, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find BSX insider trading activity (Form 4)?
SignalX aggregates every BSX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does BSX file with the SEC?
Boston Scientific (BSX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BSX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Boston Scientific (BSX).
What is BSX's SEC CIK number?
Boston Scientific (BSX)'s SEC CIK (Central Index Key) number is 885725. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 885725 to look up all BSX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find BSX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Boston Scientific (BSX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Boston Scientific SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 32+ filings.